We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J's (JNJ) COVID-19 Jab Under EU Review for Rare Blood Clots
Read MoreHide Full Article
The European Medicines Agency (“EMA”) safety committee, Pharmacovigilance Risk Assessment Committee (“PRAC”) began a review to assess reports of blood clots in a few individuals who had taken the J&J (JNJ - Free Report) one-shot COVID-19 vaccine.
The EMA’s report stated that four cases of rare clots accompanied by low blood platelets have been identified after vaccination with J&J’s jab. One of the cases was fatal.
J&J’s single-shot COVID-19 vaccine is presently approved for emergency use in the United States and was granted Conditional Marketing Authorization (CMA) by the European Commission last month. However, the vaccine has not yet been rolled out in European countries. Though such blood clot reports raise safety issues, a causal link between J&J’s vaccine and these rare events has not been established. PRAC is studying the cases and will give its decision of whether regulatory action is needed.
J&J’s shares were down 1% on Apr 9 after the blood clot reports emerged. This year so far, J&J’s shares have risen 2.4% against a decrease of 0.1% for the industry.
J&J is the second company whose COVID-19 vaccine is being investigated for rare blood clot events.
Last week, The UK’s Medicines and Healthcare products Regulatory Agency and EMAfound a “possible link” between AstraZeneca’s COVID-19 vaccine and extremely rare blood clot events. The World Health Organization also said that a “causal relationship” between the vaccine and blood clot risk factors events is probable. However, all these regulatory bodies maintained that that the vaccine’s benefits outweigh the risks. The PRAC recommended to list the unusual blood clots with low blood platelets as a rare side effect of the vaccine. The PRAC has also started a review to assess five reported cases of a rare disorder called capillary leak syndrome in people who were inoculated with the AstraZeneca jab. However, the PRAC states it was not clear whether these events were linked to the vaccine.
Meanwhile, U.K’s Joint Committee on Vaccination and Immunisation recommended that individuals below 30 years of age should opt for an alternative vaccine available in the country.
Some countries have restricted use of AstraZeneca’s in younger people after the review results were published.
Please note that J&J and AstraZeneca’s vaccines have been developed using adenovirus technologieswhile the other two vaccines, which have been launched, Pfizer (PFE - Free Report) -BioNTech’s (BNTX - Free Report) BNT162b2 and Moderna’s (MRNA - Free Report) mRNA-1273 vaccines are mRNA-based vaccines. Some investors are of the opinion that Moderna and Pfizer/BioNTech may benefit from safety issues related with J&J and AstraZeneca’s COVID-19 vaccines.
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
J&J's (JNJ) COVID-19 Jab Under EU Review for Rare Blood Clots
The European Medicines Agency (“EMA”) safety committee, Pharmacovigilance Risk Assessment Committee (“PRAC”) began a review to assess reports of blood clots in a few individuals who had taken the J&J (JNJ - Free Report) one-shot COVID-19 vaccine.
The EMA’s report stated that four cases of rare clots accompanied by low blood platelets have been identified after vaccination with J&J’s jab. One of the cases was fatal.
J&J’s single-shot COVID-19 vaccine is presently approved for emergency use in the United States and was granted Conditional Marketing Authorization (CMA) by the European Commission last month. However, the vaccine has not yet been rolled out in European countries. Though such blood clot reports raise safety issues, a causal link between J&J’s vaccine and these rare events has not been established. PRAC is studying the cases and will give its decision of whether regulatory action is needed.
J&J’s shares were down 1% on Apr 9 after the blood clot reports emerged. This year so far, J&J’s shares have risen 2.4% against a decrease of 0.1% for the industry.
J&J is the second company whose COVID-19 vaccine is being investigated for rare blood clot events.
Last week, The UK’s Medicines and Healthcare products Regulatory Agency and EMAfound a “possible link” between AstraZeneca’s COVID-19 vaccine and extremely rare blood clot events. The World Health Organization also said that a “causal relationship” between the vaccine and blood clot risk factors events is probable. However, all these regulatory bodies maintained that that the vaccine’s benefits outweigh the risks. The PRAC recommended to list the unusual blood clots with low blood platelets as a rare side effect of the vaccine. The PRAC has also started a review to assess five reported cases of a rare disorder called capillary leak syndrome in people who were inoculated with the AstraZeneca jab. However, the PRAC states it was not clear whether these events were linked to the vaccine.
Meanwhile, U.K’s Joint Committee on Vaccination and Immunisation recommended that individuals below 30 years of age should opt for an alternative vaccine available in the country.
Some countries have restricted use of AstraZeneca’s in younger people after the review results were published.
Please note that J&J and AstraZeneca’s vaccines have been developed using adenovirus technologieswhile the other two vaccines, which have been launched, Pfizer (PFE - Free Report) -BioNTech’s (BNTX - Free Report) BNT162b2 and Moderna’s (MRNA - Free Report) mRNA-1273 vaccines are mRNA-based vaccines. Some investors are of the opinion that Moderna and Pfizer/BioNTech may benefit from safety issues related with J&J and AstraZeneca’s COVID-19 vaccines.
J&J currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>